Circulating tumour DNA as a predictive biomarker for tumour response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer.

Lung India · 2025 · PMC12617573 · PMID 41129575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A 50% cut-off for response as well as a baseline ctDNA 0f 0.3 ng/microlitre showed a trend for better PFS in these patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.